ArticleMedicine2026
The predictive value of the systemic immune-inflammation index in chronic thromboembolic pulmonary hypertension.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The systemic immune-inflammation index (SII) is associated with the severity and progression of vascular disorders. However, the relationship between SII and chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. This study aimed to investigate for the first time the predictive value of SII for the development of CTEPH in patients with a history of unprovoked acute pulmonary embolism (PE). This retrospective case-control study included 62 patients with unprovoked acute PE for the first time. Thirty patients with CTEPH and 32 without CTEPH were compared in terms of baseline and follow-up clinical, echocardiographic, and laboratory parameters obtained at least 3 months after the index event. Univariate and multivariate logistic regression analyses were performed to determine predictors of CTEPH. The diagnostic performance of the SII was evaluated using receiver operating characteristic curve analysis. Among the baseline laboratory parameters related to SII, only platelet count (308 [237-339] vs 259 [207-283], P = .028) was significantly higher in the CTEPH group, whereas SII did not differ significantly between the groups. During follow-up beyond 3 months, neutrophil count (5.4 [3.6-6.4] vs 4 [3.3-4.8], P = .01), platelet count (313 [219-376] vs 251 [201-295], P = .02), and SII (1614 [607-2147] vs 566 [417-727], P < .001) were significantly higher, whereas lymphocyte count (1.4 ± 0.5 vs 1.9 ± 0.5, P < .001) was significantly lower in the CTEPH group. Multivariate logistic regression analysis demonstrated that the SII was an independent predictor of CTEPH (odds ratio 1.003 [1.000-1.005], P = .02). Receiver operating characteristic curve analysis showed that the SII had moderate diagnostic performance for predicting CTEPH (area under the curve = 0.797; 95% confidence interval, 0.682-0.912; P < .001), with an optimal cutoff value of 626.7. The SII may represent a practical and easily accessible biomarker for identifying patients at risk of developing CTEPH during follow-up after the first episode of unprovoked acute PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.